<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25831207</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1414-431X</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas</Title><ISOAbbreviation>Braz J Med Biol Res</ISOAbbreviation></Journal><ArticleTitle>Comparative pathogenicity of Coxsackievirus A16 circulating and noncirculating strains in vitro and in a neonatal mouse model.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>426</EndPage><MedlinePgn>420-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1590/1414-431X20144298</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0100-879X2015005044298</ELocationID><Abstract><AbstractText>An enterovirus 71 (EV71) vaccine for the prevention of hand, foot, and mouth disease (HMFD) is available, but it is not known whether the EV71 vaccine cross-protects against Coxsackievirus (CV) infection. Furthermore, although an inactivated circulating CVA16 Changchun 024 (CC024) strain vaccine candidate is effective in newborn mice, the CC024 strain causes severe lesions in muscle and lung tissues. Therefore, an effective CV vaccine with improved pathogenic safety is needed. The aim of this study was to evaluate the in vivo safety and in vitro replication capability of a noncirculating CVA16 SHZH05 strain. The replication capacity of circulating CVA16 strains CC024, CC045, CC090 and CC163 and the noncirculating SHZH05 strain was evaluated by cytopathic effect in different cell lines. The replication capacity and pathogenicity of the CC024 and SHZH05 strains were also evaluated in a neonatal mouse model. Histopathological and viral load analyses demonstrated that the SHZH05 strain had an in vitro replication capacity comparable to the four CC strains. The CC024, but not the SHZH05 strain, became distributed in a variety of tissues and caused severe lesions and mortality in neonatal mice. The differences in replication capacity and in vivo pathogenicity of the CC024 and SHZH05 strains may result from differences in the nucleotide and amino acid sequences of viral functional polyproteins P1, P2 and P3. Our findings suggest that the noncirculating SHZH05 strain may be a safer CV vaccine candidate than the CC024 strain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>G C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>X F</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>W Y</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Med Biol Res</MedlineTA><NlmUniqueID>8112917</NlmUniqueID><ISSNLinking>0100-879X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25831207</ArticleId><ArticleId IdType="pmc">PMC4445665</ArticleId><ArticleId IdType="doi">10.1590/1414-431X20144298</ArticleId><ArticleId IdType="pii">S0100-879X2015005044298</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, et al. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother. 2014;10:360&#x2013;367. doi: 10.4161/hv.27087.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.27087</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Repass GL, Palmer WC, Stancampiano FF. Hand, foot, and mouth disease: Identifying and managing an acute viral syndrome. Cleve Clin J Med. 2014;81:537&#x2013;543. doi: 10.3949/ccjm.81a.13132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.81a.13132</ArticleId><ArticleId IdType="pubmed">25183845</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis. 2009;15:1689&#x2013;1691. doi: 10.3201/eid1510.090594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1510.090594</ArticleId><ArticleId IdType="pmc">PMC2866411</ArticleId><ArticleId IdType="pubmed">19861078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CY, Li LF, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J. 2004;23:275&#x2013;276. doi: 10.1097/01.inf.0000115950.63906.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000115950.63906.78</ArticleId><ArticleId IdType="pubmed">15014311</ArticleId></ArticleIdList></Reference><Reference><Citation>Legay F, Leveque N, Gacouin A, Tattevin P, Bouet J, Thomas R, et al. Fatal coxsackievirus A-16 pneumonitis in adult. Emerg Infect Dis. 2007;13:1084&#x2013;1086. doi: 10.3201/eid1307.070295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1307.070295</ArticleId><ArticleId IdType="pmc">PMC2878248</ArticleId><ArticleId IdType="pubmed">18214187</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyckmans T, Wollants E, Janssens A, Schoemans H, Lagrou K, Wauters J, et al. Coxsackievirus A16 Encephalitis during Obinutuzumab Therapy, Belgium, 2013. Emerg Infect Dis. 2014;20:913&#x2013;915. doi: 10.3201/eid2005.131766.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2005.131766</ArticleId><ArticleId IdType="pmc">PMC4012818</ArticleId><ArticleId IdType="pubmed">24751368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhu C, Bao W, Zhao K, Niu J, Yu XF, et al. Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One. 2012;7: doi: 10.1371/journal.pone.0032405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032405</ArticleId><ArticleId IdType="pmc">PMC3315555</ArticleId><ArticleId IdType="pubmed">22479324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Xu WB, Xia JL, Liang ZL, Liu Y, Zhang XF, et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol. 2014;95:1083&#x2013;1093. doi: 10.1099/vir.0.065003-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.065003-0</ArticleId><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Chang J, Liu X, Yang J, Guo H, Wei W, et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol. 2014;95:1083&#x2013;1093. doi: 10.1099/vir.0.063560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.063560-0</ArticleId><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Guo H, Li J, Ren S, Wei Z, Bao W, et al. Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16. PLoS One. 2014;9: doi: 10.1371/journal.pone.0094746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094746</ArticleId><ArticleId IdType="pmc">PMC3988102</ArticleId><ArticleId IdType="pubmed">24736564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Yang F, Zhao R, Zhao L, Guo D, Jin Q. Identification of small interfering RNAs which inhibit the replication of several Enterovirus 71 strains in China. J Virol Methods. 2009;159:233&#x2013;238. doi: 10.1016/j.jviromet.2009.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.04.002</ArticleId><ArticleId IdType="pubmed">19490979</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Han X, Wang G, Hu W, Zhang W, Yu XF. Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis. 2011;17:1537&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381541</ArticleId><ArticleId IdType="pubmed">21801645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A, Tagaya I, Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978;9:60&#x2013;63. doi: 10.1159/000148922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000148922</ArticleId><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Koike S. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J Virol. 2011;85:4937&#x2013;4946. doi: 10.1128/JVI.02358-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02358-10</ArticleId><ArticleId IdType="pmc">PMC3126200</ArticleId><ArticleId IdType="pubmed">21389126</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>